drugset / Trial / NCT01333397

Safety and Efficacy Study of Dysport RU and Glabellar Lines

NCT01333397

Phase 2 Completed 176 enrolled Ipsen
RandomizedParallel-groupTriple-blindTreatment

Summary

The primary objective is to assess the dose response versus placebo of a single treatment of Dysport RU (Dysport RU, Ready to Use, for injection), for the improvement in appearance of moderate to severe glabellar lines at maximum frown.

Timeline

Start
2011-03
Primary completion
2011-09
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Botulinum toxin type A Protein / enzyme biologic 20 iu Intramuscular
Comparator Botulinum toxin type A Protein / enzyme biologic 50 iu Intramuscular
Comparator Botulinum toxin type A Protein / enzyme biologic 75 iu Intramuscular

Indications

No indication recorded.